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Background: There is currently a renaissance of interest in the many functions of cerebrospinal fluid (CSF). Altered
flow of CSF, for example, has been shown to impair the clearance of pathogenic inflammatory proteins involved in
neurodegenerative diseases, such as amyloid-β. In addition, the role of CSF in the newly discovered lymphatic system of
the brain has become a prominently researched area in clinical neuroscience, as CSF serves as a conduit between the
central nervous system and immune system.
Main body: This article will review the importance of CSF in regulating normal brain development and function, from the
prenatal period throughout the lifespan, and highlight recent research that CSF abnormalities in autism spectrum disorder
(ASD) are present in infancy, are detectable by conventional structural MRI, and could serve as an early indicator of altered
neurodevelopment.
Conclusion: The identification of early CSF abnormalities in children with ASD, along with emerging knowledge of the
underlying pathogenic mechanisms, has the potential to serve as early stratification biomarkers that separate children
with ASD into biological subtypes that share a common pathophysiology. Such subtypes could help parse the
phenotypic heterogeneity of ASD and map on to targeted, biologically based treatments.
Keywords: Autism spectrum disorder, Biomarkers, Brain development, Brain enlargement, Cerebrospinal fluid,
Early risk signs, Extra-axial cerebrospinal fluid, Glymphatic system, Heterogeneity, Infancy, Lateral ventricles,
Neural meningeal lymphatic system, Neuroinflammation, Stratification biomarkerIntroduction
Until recently, it was thought that the main purpose of
cerebrospinal fluid (CSF) was merely to provide protective
cushioning of the brain, but new discoveries in the last
5 years have revealed that CSF plays a critical role in brain
development and function, both prenatally and throughout
the lifespan. It is now recognized that the two primary
functions of normal CSF circulation are as follows: (1) de-
livery of growth factors and other signaling molecules
necessary for healthy neural growth [1–4] and (2) cleaning
of the brain by removing neurotoxins and metabolic waste
byproducts of neuronal function [5–7]. Here, we will briefly
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CSF production and delivery of growth factors
The CSF system originates in the first few weeks of ges-
tation when the neural tube closes and is filled with CSF
[8]. As the neural tube elongates, it forms the central
canal of the central nervous system (CNS)—with the
most rostral end becoming the walls of the lateral ventri-
cles and the caudal end becoming the spinal cord [8].
CSF is continually produced by the choroid plexus in
the ventricles, where it delivers signaling molecules to
progenitor cells that originate on the apical surface of
the ventricles [1–4]. With signaling from growth factors
supplied by circulating CSF, these progenitor cells prolif-
erate on the ventricular surface into immature neurons
[1–4], which then migrate from the ventricular surface
to different layers and regions of the developing cerebral
cortex, where finally they will aggregate and differentiate
to form identifiable parts of the brain [8]. Thus, the CSFle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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while circulating through the CNS—play a driving force
in regulating early brain development and neural cell
proliferation and migration [3].CSF absorption and cleaning of
neuroinflammation
Throughout early development and the lifespan, the
production of CSF needs to be continuously balanced
by the corresponding absorption of CSF. The brain
continuously produces CSF at a rate of 500 cm3 each
day [9] and then must be efficiently absorbed and
recycled, as the brain typically only holds 150 cm3 of
CSF at any given time [9]. In fact, a fresh batch of CSF
is produced and recycled four times per day [9].
Freshly produced CSF circulates from the lateral,
third, and fourth ventricles to the cisterns of the brain
and then flows into the subarachnoid space, where it
envelops the cortical convexities of the brain.
Seventy-five percent of the CSF volume in the brain is
located in the subarachnoid space; and 25% is located
in the ventricles [9]. From the subarachnoid space,
there is influx of CSF into the interstitial space, whereFig. 1 Schematic of CSF circulation, CSF outflow systems, and the anatomy
in the ventricles, where it delivers growth factors to progenitor cells that o
neurons and migrate to form the cerebral cortex. CSF circulates from the la
flows into the subarachnoid space, where it envelops the cortical convexiti
is retrograde influx of CSF into the parenchyma, where CSF and interstitial
course throughout the brain. Astrocytes lining the perivascular space aid in
which are continually secreted by neurons as byproducts of neuronal activ
these inflammatory waste products returns to the subarachnoid space (EA-
granulations.CSF and interstitial (ISF) fluid interact within the par-
enchyma to remove catabolic waste proteins that have
been produced as byproducts of neuronal function [5].
Finally, the subarachnoid CSF drains into neural
lymphatic vessels [10] and through one-way valves
called arachnoid granulations [11]. Thus, while the
production of freshly circulating CSF allows for the
delivery of nutrients and peptides to neurons, the cor-
responding absorption of CSF provides the necessary
removal of toxic, catabolic waste byproducts of neur-
onal function [5]. Conversely, perturbations in CSF
circulation can impair clearance of harmful substances
that accumulate in the brain and lead to
neuroinflammation [6]. This “cleaning system” of the
brain—and the critical role of normal CSF circulation
in this cleaning system—has only recently been dis-
covered. As discussed later in this review, these
discoveries have led to new hypotheses about what
happens when the CSF system is not functioning nor-
mally and the potential consequences of impaired
clearance of harmful neuroinflammation [5–7]. See
Fig. 1 for a schematic depicting the circulation of CSF,
the CSF outflow systems, and the anatomy of various
CSF compartments.of various CSF compartments. CSF is produced by the choroid plexus
riginate on the surface of the ventricles, and then proliferate into
teral, third and fourth ventricles to the cisterns of the brain, and then
es of the brain (EA-CSF). Inset box: From the subarachnoid space, there
fluid interact in the perivascular space, alongside blood vessels that
transporting fluid that removes inflammatory waste proteins (e.g., Aβ),
ity and would otherwise build up in the brain. Finally, fluid carrying
CSF) and drains into meningeal lymphatic vessels and arachnoid
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In vivo structural magnetic resonance imaging (MRI)
can measure the volume of different CSF compartments,
which can serve as indirect markers of altered CSF
production and absorption.
Lateral ventricle volume in ASD
Deviation from typical levels of CSF production, repre-
sented through an enlargement or reduction in lateral
ventricle (LV) volumes, has been a research focus in
multiple neurodevelopmental disorders [9]. However,
the findings related to LV volume in ASD have been in-
consistent. Several studies have reported no differences
in LV volume in school-aged children [12] and adults
with ASD [13, 14], compared to controls. In contrast to
these findings of normal CSF volume in the ventricles,
there is evidence for increased volume of CSF located
outside the ventricles (i.e., CSF volume contained in all
of the cisterns and entire subarachnoid space) [14], as
well as increased volume of global CSF across the
whole brain [15].
Extra-axial CSF volume in ASD
Studies of infants at high familial risk for ASD have
indicated that the defining diagnostic features of ASD,
such as social deficits, are not present at 6 months of
age, but begin to emerge between 12 and 24months
[16–18]. We recently identified a brain anomaly at 6
months of age, prior to the onset of diagnosticFig. 2 a T2-weighted images of an infant with a normal MRI at 6 months o
age. b Similar T2-weighted images of an infant with excessive extra-axial C
indicated as brighter regions in these images. Images are of a horizontal se
through the brain.]symptoms, in high-risk infants who were ultimately di-
agnosed with ASD (HR-ASD) [19]. At 6 months, infants
who later developed ASD (n = 10) had increased “extra--
axial CSF,” which is an excessive amount of CSF in the
subarachnoid space surrounding the cortical surface of
the brain (see Fig. 2). (This study developed a novel
method in infant MRIs to quantify the volume of
extra-axial CSF (EA-CSF) in the dorsal subarachnoid
space above the horizontal plane of the
anterior-posterior commissure, thereby avoiding ventral
regions that contain cisterns, sinuses, and vasculature
that should not be classified as extra-axial CSF.) In-
creased volume of EA-CSF at 6 months of age preceded
the onset of diagnostic symptoms in infants later diag-
nosed with ASD and remained abnormally elevated at
12 and 24 months of age [19]. Increased EA-CSF was
predictive of later autism diagnosis, and greater EA-CSF
at 6 months was associated with more severe autism
symptoms at the time of diagnosis at 36 months of age
[19], suggesting that the severity of this early CSF anom-
aly is associated with the severity of later autism
symptoms.
The finding in Shen et al. 2013 [19] was the first MRI
report of a structural brain alteration in infants who devel-
oped ASD, but it was a relatively small sample (N = 55
total infants studied, 10 of whom developed ASD), and
thus warranted replication in a larger, independent sam-
ple. In Shen et al. 2017 [20], the findings were replicated
and extended in a larger, independent cohort of infantsf age, who was confirmed as having typical development at 2 years of
SF at 6 months, who was diagnosed with ASD at 2 years of age. [CSF is
ction (left), coronal section (middle), and sagittal section (right)
Fig. 3 Infants later diagnosed with autism spectrum disorder (ASD)
had abnormally increased extra-axial CSF by 6 months, which
remained significantly elevated through 24 months. [Least squares
means are adjusted for age, sex, total cerebral volume, and scan site.
Error bars ± 1 SEM. *p = .005 vs. both control groups (high risk-
negative and vs. low risk-negative). Percent differences and Cohen’s
d effect sizes are calculated in relation to the high risk-negative
group.] (Adapted from Shen et al. [20])
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ond study, infants who later developed ASD had 18%
more EA-CSF at 6months than the control groups
(HR-negative and LR groups). EA-CSF volume remained
persistently elevated through 24months of age, relative to
controls (Fig. 3). This replication study included one of
the largest longitudinal MRI samples of infants who devel-
oped ASD and thus had the opportunity to examine sub-
groups within ASD to determine if EA-CSF at 6months
could stratify children by the severity of symptoms the
children would exhibit at the age of diagnosis. The severity
categories were based on well-validated, empirically de-
rived cutoffs on the Autism Diagnostic Observation
Schedule (ADOS) that index the severity of autism symp-
toms [21]. Infants who were later diagnosed with the most
severe autism symptoms had a more pronounced increase
of EA-CSF—nearly 25% greater EA-CSF at 6months than
controls [20]. Consistent with the first study, the second
study demonstrated that the amount of EA-CSF at 6
months of age preceded the onset of autistic symptoms,
was predictive of later autism diagnosis, and was associ-
ated with severity of later autism symptoms [20].
We recently published a third study of a large cohort
of preschool-aged children with ASD (N = 159), who
were scanned at 2–4 years of age and had 15% more
EA-CSF at this age than children with typicaldevelopment (N = 77) [22]. This third cohort of children
with ASD extended the findings from the previous infant
studies because it comprised both high-risk and low-risk
children at preschool-age: (a) children diagnosed with
ASD who were “high-risk” like the children in the infant
studies (i.e., came from a multiplex family with more
than one child with ASD in the family) and (b) children
with ASD who were “low-risk” (i.e., came from a simplex
family in which they were the only child with ASD).
High-risk and low-risk children with ASD had nearly
identical volumes of EA-CSF, and both had significantly
greater EA-CSF than typically developing controls at
2-4 years of age [22]. In summary, increased EA-CSF ap-
pears to be a reliable brain anomaly that has been found
in three independent cohorts of children with ASD, re-
gardless of familial risk background, from infancy
through preschool age [19, 20, 22].
While these studies were the first to report an associ-
ation between increased EA-CSF and ASD, several previ-
ous reports in the general pediatrics literature have
reported an association between increased EA-CSF and
motor delays [23–26]. Since early motor delays have also
been widely reported in infants who are later diagnosed
with ASD [18, 27, 28], the Shen et al. 2017 [20] study
tested the hypothesis that EA-CSF would be associated
with early motor deficits in ASD. Indeed, using both dir-
ect examination and parent-interviews of motor ability,
increased EA-CSF at 6 months was significantly associ-
ated with deficits in motor ability at 6 months (but not
non-motor abilities) in infants later diagnosed with ASD
[20]. This is notable given the emerging evidence that
motor problems are an early inherent feature of ASD.
There are strong genetic associations with motor
problems in ASD [29], and coupled with the presence
of deficits in fine and gross motor skills at 6 months of
age [27, 30] and increased motor stereotypies at 12
months of age [31], this collective evidence points to
abnormal development of motor systems prior to the
onset of the hallmark diagnostic symptoms. The speci-
ficity of the association between increased EA-CSF
volume at 6 months and poorer motor skills at 6
months [20] suggests that increased EA-CSF may be
related to motor development during the prodromal
period in ASD, before behaviors diagnostic of ASD
typically arise. Future studies are needed to elucidate
the potential relationship between EA-CSF, motor
function, and other putative motor systems of the
brain (e.g., basal ganglia, cerebellum).
Relationship between extra-axial CSF and lateral ventricle
volume in ASD
In both studies of infants who developed ASD, LV
volume was not significantly enlarged compared to con-
trols, despite increased volume of extra-axial CSF [19,
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not significantly correlated with each other [20]. This is
consistent with reports in the general pediatrics litera-
ture that increased EA-CSF volume is usually found in
the absence of LV enlargement [23, 32, 33], and intracra-
nial pressure is usually normal [11, 23]. LV volume was
also found to be highly variable within the ASD group
and across infancy, whereas EA-CSF was persistently el-
evated from 6 to 24months in infants later diagnosed
with ASD [19, 20]. Collectively, the pattern of neuroana-
tomical findings in infancy is consistent with studies in
older children and adults with ASD reviewed above,
demonstrating that CSF volume is relatively normal in-
side the ventricles but abnormally increased in the
extra-axial space surrounding the brain. Combined with
the finding that lateral ventricle volume and extra-axial
CSF volume are not correlated, the extant evidence in
ASD indicates there is a decoupling between the volume
of CSF in the lateral ventricles and the volume of CSF in
the extra-axial space. This pattern of neuroanatomical
anomalies raises the possibility that there is an imbal-
ance between CSF production and absorption in ASD,
such that normal-sized lateral ventricles may reflect
relatively normal CSF production, whereas increased
extra-axial CSF may be a potential marker of impaired
CSF circulation and absorption. Elucidating the under-
lying physiology of these anatomical CSF findings will
require future studies using animal models or non-
invasive CSF flow studies in children.
Relationship between extra-axial CSF and brain tissue
volume in ASD
Is increased EA-CSF volume simply the result of brain tis-
sue loss? In neurodegenerative conditions like dementia, in-
creased extra-axial CSF arises because CSF fills in the
subarachnoid space that was previously occupied by atro-
phic brain tissue [34, 35]. However, in all three studies in
infants and preschoolers diagnosed with ASD, there was a
robust, positive association between extra-axial CSF volume
and total cerebral volume [19, 20, 22], with 22% shared
variance between these two measures [22]. If increased
EA-CSF was due to loss of brain tissue then a negative
association between CSF and brain volume would be ex-
pected instead. Thus, increased EA-CSF in young children
with ASD is likely related to different mechanisms than
what is observed in degeneration of brain tissue.
While EA-CSF volume has been found to be positively
associated with overall brain volume [19, 20], there are
possible relationships with other changes in gray and
white matter that have yet to be explored. For example,
abnormal development of cortical gray and white matter
have been reported [36–41] in the same cohort of
infants with increased EA-CSF [20]. Furthermore, other
studies have reported subcortical abnormalities inperiventricular regions (e.g., basal ganglia) [42, 43] that
might relate to altered CSF anatomy. Future studies are
therefore needed to further interrogate the relationships
between EA-CSF, lateral ventricles, and cortical and sub-
cortical gray and white matter anatomy.
CSF abnormalities in the context of early brain
overgrowth in ASD
One of the most consistent findings from previous neu-
roimaging studies in ASD has been that brain size is sig-
nificantly enlarged in early childhood, so it is important
to evaluate CSF abnormalities during infancy in the con-
text of early brain enlargement. The first direct MRI evi-
dence of brain enlargement prior to age 2 years was
reported in the same 2013 cohort of 55 infants (10 of
whom developed ASD), who were longitudinally imaged
between 6 and 24months [19]. The HR-ASD group had
significantly faster growth trajectories of total brain vol-
ume, such that by 12–24months of age the group had
larger brain volumes than the controls, on average. This
was the first study to prospectively measure longitudinal
brain volumes during infancy in ASD [19].
A larger study evaluated the individual trajectories of 15
HR-ASD infants, who had data at all three serial MRI
scans at 6, 12, and 24months of age [41], compared to a
large sample of control infants (91 HR infants who did
not develop ASD; 42 low-risk infants). In addition to
measuring total brain volume, this study also decomposed
brain volume into precise anatomical measures of cortical
surface area and cortical thickness, which both contribute
to overall brain volume but are controlled by distinct gen-
etic mechanisms [44]. HR-ASD infants had increased rate
of cortical surface area expansion from 6 to 12months,
followed by an increased growth rate of total brain volume
from 12 to 24months, compared to controls [41].
Taken together, these infant studies show that infants
who later develop ASD have elevated levels of EA-CSF at
6months [19, 20], increased growth rate of the cortical
surface between 6 and 12months [41], and total brain vol-
ume overgrowth between 12 and 24months of age [19,
41]. Thus, brain changes in ASD are present during the
prodromal period prior to diagnosis, preceding behavioral
differences. At 6months of age, brain size is normal but
there is an excessive amount of EA-CSF [19, 20]. This is a
time when the first behavioral differences in ASD are de-
tectable, including motor delays [18, 27, 28], and excessive
EA-CSF at 6 months was associated with early motor defi-
cits at 6months [20]. Between 6 and 12months of age,
there is rapid expansion of cortical surface area [41],
which is concurrent with the onset of sensory and atten-
tion problems, such as deficits in visual reception [27] and
orienting to salient social cues in the environment [45].
Between 12 and 24months, there is increased growth rate
of total brain volume [19, 41], which was reported to be
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early changes in brain development in the first year of life
coincide with the age when early sensorimotor and visual
orienting differences tend to emerge, which are followed
by social deficits in the second year of life and the consoli-
dation of behaviors that are diagnostic of ASD [46].
The impact of CSF dysfunction on brain
development
How might increased extra-axial CSF in infancy and
early brain overgrowth be related? CSF circulation
serves as a means of transporting important growth
factors and signaling molecules throughout the brain
that are required for the normal development of the
neocortex, such as insulin-like growth factors (IGF1
and IGF2) [1, 3, 4, 9]. Increased EA-CSF volume is a
reflection of stagnant or reduced circulation of CSF, as
evidenced by consistent findings from several MRI
studies that measured the dynamic flow of CSF (using
non-invasive diffusion imaging [47] or injected iso-
topes and contrast agents [19, 23, 24, 48]). Stagnation
of CSF leads to the accumulation of neuromodulators
in brain tissue that may alter the extracellular environ-
ment of neurons and impact their growth and function
[5, 49]. An imbalance between CSF production and ab-
sorption alters the concentration of these factors and
could alter cortical development [50]. For example,
stagnation of CSF flow in animal models leads to an al-
teration of neurogenesis and premature migration of
progenitor cells from the apical surface of the ventri-
cles [50]. An imbalance in concentration between IGF1
and IGF2 can result in opposing brain phenotypes of
microcephaly and macrocephaly in animal models [3].
Indeed, there is evidence that the composition of CSF
drawn from the subarachnoid space in infants with
increased extra-axial CSF has a markedly higher pro-
tein concentration compared to CSF drawn from the
ventricles or spinal column [51], and also compared to
CSF in normal infants [48]. Future studies are needed
to test the hypothesis that stagnant or elevated EA-
CSF in ASD has a different composition of trophic
growth factors (IGF1, IGF2) [1, 3, 4, 9].
The impact of CSF dysfunction on the clearance of
neuroinflammation
Is it possible that increased accumulation of CSF over
the surface of the brain leads to neuroinflammation?
The primary function of continuous CSF outflow is the
removal of inflammatory byproducts of brain metabol-
ism, such as amyloid-β (Aβ) and tau protein [6, 9]. In
normative brain development, the amount of extra-axial
CSF in the subarachnoid space increases from birth to 7
months, declines between 12 to 24 months, and is min-
imal by 24months [52]. In ASD, the extant evidenceindicates that extra-axial CSF is abnormally elevated
until 3 years of age [19, 20, 22], which suggests that the
normal mechanisms for outflow of CSF may be aberrant
in infants who develop ASD.
There are three clearance systems that are responsible
for CSF outflow and clearance of Aβ (see Fig. 1 for a
schematic of the various CSF outflow systems). First, in
the mature brain, return of subarachnoid EA-CSF to the
venous circulation takes place through reabsorption into
arachnoid granulations—one-way valves that drain into
the dural venous sinuses (e.g., superior sagittal sinus)
[53]. However, arachnoid granulations are not open at
birth and only mature over the first 18 months of life
[54, 55]. The immaturity of arachnoid granulations in
infancy may cause CSF to accumulate in the subarach-
noid space, leading to elevated extra-axial CSF volume
[56, 57]. Second, beyond the arachnoid granulations,
there is new evidence that CSF can exit the brain in an-
other way. Two-photon imaging studies from the past
few years have indicated that bulk flow of CSF and inter-
stitial fluid (i.e., fluid in the interstitial space) contributes
to a larger portion of Aβ clearance than previously
thought [5–7, 58]. The flow of fluid—through the inter-
stitial space where it clears extracellular Aβ, and exiting
through the subarachnoid space—is facilitated by astro-
glial aquaporin-4 (AQP4) channels and thus is named
the glymphatic (glial + lymphatic) system [5–7, 58].
Third, the recent discovery of the meningeal lymphatic
system provides another clearance route for CSF and
inflammatory proteins [10]. These meningeal lymphatic
vessels provide a direct path between the nervous and
immune systems for immune cells to exit the CNS [59]
(see Fig. 1). Because these clearance systems act together
to drive Aβ from the brain, alterations in any given sys-
tem could contribute to altered neurophysiology and
accumulation of neuroinflammation [59].Potential links between CSF dysfunction, the immune
system, and brain development in ASD
The link between CSF flow, neuroinflammation, and brain
development has been informed by recent discoveries in
neurodegenerative disorders. Failure of Aβ clearance is in-
creasingly recognized in the pathogenesis of Alzheimer
disease [59]. The pathological hallmark of Alzheimer dis-
ease is the accumulation of toxic proteins—Aβ plaques and
tau tangles [59]. Now, there is emerging evidence that CSF
clearance of Aβ is impaired in both early-onset and
late-onset forms Alzheimer disease, resulting in excessive
accumulation of toxic forms of Aβ [59]. In fact, Aβ depos-
ition can be elevated during the presymptomatic period of
Alzheimer disease, years or even decades before the pres-
entation of the hallmark neurological and cognitive symp-
toms [59, 60].
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crease in CSF production in the first year of normal
brain development [61], which may not be a problem for
typical infants whose CSF production is balanced by
proper absorption through the mechanisms discussed
above. However, there may be an imbalance between
CSF production and CSF drainage in infants with exces-
sive extra-axial CSF who later develop autism [19, 20].
CSF is recycled at a much slower rate in early life [9],
and there is a higher ratio of CSF-to-brain volume in in-
fancy [61]. Collectively, these factors contribute to the
infant brain having less ability than the mature brain to
eliminate inflammatory metabolites and toxins, making
it more vulnerable to damage if the CSF system is per-
turbed [9].
In ASD, there are three lines of converging evidence
that support a potential link between increased extra-axial
CSF, impaired CSF circulation, and buildup of neuroin-
flammation (e.g., Aβ). First, there is mounting evidence of
increased levels of Aβ in individuals with ASD, which has
been found in neurons from postmortem brain tissue,
blood, and peripheral CSF [62–65]. Second, sleep prob-
lems are commonly found in ASD [66, 67], and disrupted
sleep hinders the flow of CSF and its ability to clear Aβ
[6]. Consistent with this proposed link between sleep
problems and CSF abnormalities, we found that worse
sleep problems in preschool children with ASD (N=159)
were associated with greater EA-CSF volume [22]. During
natural sleep, there is a 60% increase in the influx of CSF
compared to the awake state, as the exchange of CSF be-
tween the interstitial space and the subarachnoid space is
accelerated during sleep [6]. This increased flow of CSF
during normal sleep facilitates the increased clearance of
Aβ, which is continually secreted by neurons and needs to
be continually removed by the efficient flow of CSF [6].
Thus, it is possible that sleep disturbances in ASD may
impair the normal restorative function of sleep to clear in-
flammatory byproducts that accumulate in the awake
brain. Of course, this proposed mechanism needs to be
tested with animal models in order to elucidate the patho-
physiology underlying this reported relationship between
sleep problems and increased EA-CSF in ASD [22].
Third, the recent discovery of the meningeal lymphatic
system [10], and its reliance on normal drainage of CSF,
raises the possibility that the lymphatic system and im-
mune system are involved in increased extra-axial CSF.
A recent report [68] demonstrated that impaired func-
tion of meningeal lymphatic vessels resulted in (a) re-
duced drainage of CSF from the subarachnoid space into
the meningeal lymphatics (with no change in ventricular
volume), (b) decreased circulation of fluid through the
parenchyma and clearance of macromolecules, (c) accel-
erated Aβ accumulation in the parenchyma and sub-
arachnoid space, and (d) cognitive deficits in learningand memory. These results suggest that normal drainage
of CSF by the meningeal lymphatics is necessary for
proper cognitive function. The meningeal lymphatic ves-
sels may serve as a direct path for immune cells to exit
the CNS, and dysfunction of these vessels might have
important implications for neurological conditions asso-
ciated with altered immune responses [59]. This may be
relevant for neurodevelopmental disorders like ASD,
given the growing evidence for the interplay between the
immune system and central nervous system in neurode-
velopmental disorders [69] and that immune dysfunction
is commonly found in individuals with ASD [70–74].
Conclusions and future directions
Currently, diagnosis of autism spectrum disorder (ASD)
relies on the presence of behavioral impairments that do
not emerge until the latter part of the first and during
the second year of life [17], and thus, diagnosis is not
typically made until 3–4 years of age [75]. Early behav-
ioral differences between those who develop ASD and
those who do not have only been identified at the
group-average level (e.g., see [27]), and early behavioral
markers are not sensitive nor specific enough for
individual-level prediction of later ASD diagnosis [76].
Consequently, it is common practice to not initiate treat-
ment until after behavioral diagnosis of ASD. However,
there is emerging consensus in ASD that earlier inter-
vention is more effective than later intervention [77–80].
Thus, there is a need for both early and biologically
derived markers for ASD in infancy to help identify
which children need what type of treatment. It is im-
portant to identify not only prediction biomarkers, but
also stratification biomarkers to parse the phenotypic
heterogeneity in ASD, which is a well-recognized
impediment to developing targeted treatments. For ex-
ample, a fully cross-validated machine learning algo-
rithm relying on the amount of EA-CSF volume at 6
months predicted later ASD diagnosis at 24 months
with 66% sensitivity and 68% specificity [20]. This pre-
diction algorithm was then externally validated in a
separate sample of infants [19] (in order to test the al-
gorithm on an independent dataset), which yielded
80% sensitivity and 67% specificity in predicting ASD
diagnosis on the basis of EA-CSF volume at 6 months
[20]. This identical prediction algorithm using EA-CSF
was recently validated in a third independent sample
of preschool-aged children with 83% positive predictive
value (PPV), 84% sensitivity, and 65% specificity [22].
The findings of these studies emphasized the import-
ance of moving beyond group-level differences toward
individual-level prediction, which indicated that CSF
abnormalities are present at 6 months of age, prior to
the onset of the defining behavioral features of ASD.
Given the heterogeneity of ASD, it is unlikely that
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as the sensitivity and specificity metrics were not high
enough for EA-CSF to serve as a single stand-alone
marker for all cases on the autism spectrum. However,
the replication and reliability of the findings between
three independent cohorts (consisting of both high-
and low-risk children with ASD) [19, 20, 22] indicate
that increased EA-CSF at 6 months could be a poten-
tial early stratification biomarker that delineates one
biological subtype of ASD that shares a common
underlying biology.
In order to validate EA-CSF as a potential stratifica-
tion biomarker, several future studies must be con-
ducted to (a) determine its specificity (by comparing
to other neurodevelopmental disorders), (b) elucidate
the underlying biology (using animal models and iden-
tifying genetic associations), and (c) test potential
mechanisms using experimental approaches such as
those established by studies described above of the
glymphatic and meningeal lymphatics systems [5, 6,
10, 68]. For instance, identifying CSF flow abnormal-
ities in genetically defined syndromes of ASD—and
then conducting mechanistic experiments in the ani-
mal models of such syndromes (e.g., Fragile X, Tuber-
ous Sclerosis, Dup15q, Angelman syndrome)—would
help the field take the next step toward teasing apart
biology and developing targeted treatments.
The phenotypic heterogeneity in ASD has hampered
efforts toward targeted treatments, which has led to
major initiatives by the child psychiatry field and the
U.S. National Institute of Mental Health to identify
biological subtypes of ASD [81]. Thus, there is a need
for stratification biomarkers that can separate children
into ASD subtypes that share a common pathophysi-
ology. The clinical utility of such stratification bio-
markers would be to parse the autism spectrum into
clinically significant subtypes that map on to specific,
mechanistically targeted treatments [82].Abbreviations
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